Core Points - Clearmind Medicine Inc. has entered into securities purchase agreements with institutional investors to issue convertible promissory notes totaling up to $10 million [1][3] - The initial closing involved the issuance of notes worth $555,556 for a purchase price of $500,000 [1] - The company plans to use the proceeds from the notes for working capital, general corporate purposes, and potential acquisitions [3] Group 1 - The company will issue additional notes worth $1,944,444 for a purchase price of $1,750,000 after the effectiveness of a registration statement [3] - Clearmind may request additional purchases of notes up to $2,500,000 per quarter, totaling $7,500,000, starting three months after the second initial closing [3][4] - Each note will be issued at 90% of the principal amount, accruing interest at 4%, increasing to 14% upon default, and is to be repaid in ten equal monthly installments starting 18 months after issuance [5] Group 2 - Clearmind is focused on developing psychedelic-derived therapeutics to address under-treated health issues, including alcohol use disorder [6] - The company holds a portfolio of nineteen patent families with 31 granted patents and aims to acquire additional intellectual property [6] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [7]

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended July 31, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | July 31, | | | October 31, | | --- | --- | --- | --- | --- | | | 2025 | | | 2024 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents | $ 3,495,338 | | $ | 6,57 ...

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in the publication of an international patent application under the Patent Cooperation Treaty (PCT) [1] - The patent application covers a combination therapy of Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) aimed at treating metabolic syndrome and obesity [2] - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The collaboration has led to the filing of 13 patent families across multiple jurisdictions, focusing on innovative therapies for mental health disorders and metabolic conditions [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies, with ongoing programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [5] - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing psychedelic-derived therapeutics for health issues like alcohol use disorder, with a portfolio of 19 patent families [6]

Core Insights - Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval from Hadassah Medical Center for its Phase 1/2a clinical trial of CMND-100, aimed at treating Alcohol Use Disorder (AUD) [1][3][4] - The trial will also involve other prestigious institutions such as Yale School of Medicine and Johns Hopkins University [2] - The approval follows previous regulatory milestones, including FDA clearance of the Investigational New Drug (IND) application [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including AUD [5] - The company holds a portfolio of nineteen patent families with 31 granted patents and plans to seek additional patents as necessary [6] Clinical Trial Details - The Phase 1/2a trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption [4] - The global burden of AUD is significant, accounting for 4.7% of all deaths worldwide, highlighting the need for effective treatments [4]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a combination therapy aimed at addressing obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to tackle significant health issues, including alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, which includes 31 granted patents, and plans to seek additional patents as necessary [5] Health Challenges Addressed - The proprietary combination therapy targets obesity, which affects over 890 million people globally, and MASLD, impacting more than 30% of the adult population [2] - The treatment options for these conditions remain limited despite their widespread prevalence [2] Therapeutic Approach - The combination therapy utilizes MEAI (5-methoxy-2-aminoindane) and Palmitoylethanolamide (PEA), leveraging MEAI's pharmacological profile and PEA's anti-inflammatory and neuroprotective properties [3] - The company believes this novel approach could provide a safe and effective therapeutic alternative for patients [3] Collaboration - The patent filing is part of an ongoing collaboration with SciSparc Ltd., which is also focused on developing therapies for central nervous system disorders [3]

Core Insights - SciSparc Ltd. has filed a new international patent application in collaboration with Clearmind Medicine Inc. for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is currently developing drugs such as SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus [4] Industry Context - Obesity affects over 890 million people globally and is a significant risk factor for chronic conditions, while non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the adult population [2] - There is a limited number of treatment options available for these health challenges, highlighting the potential market opportunity for innovative therapies [2]

Core Insights - Clearmind Medicine Inc. has successfully completed site initiation at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial of CMND-100, targeting Alcohol Use Disorder (AUD) [1][2] - The trial is multinational and multi-center, assessing safety, tolerability, and pharmacokinetics of CMND-100, while also exploring early efficacy signals [2][3] - CMND-100 utilizes the molecule 5-methoxy-2-aminoindane (MEAI) and has shown promising preclinical results in reducing alcohol cravings, addressing a significant unmet need in AUD treatment [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents [5] Clinical Trial Details - The Phase I/IIa trial includes prestigious sites such as Yale School of Medicine and Johns Hopkins University, alongside TASMC and Hadassah-University Medical Center [2] - The trial is led by Prof. David Zeltser at TASMC, enhancing Clearmind's clinical network and patient enrollment [2][3]

Core Viewpoint - Clearmind Medicine Inc. is expanding its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder (AUD), by activating a new site at Johns Hopkins University and enrolling its first participant there, indicating positive momentum in its clinical development program [1][2][3]. Group 1: Clinical Trial Details - The Phase I/IIa clinical trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy indicators focusing on reducing alcohol cravings and consumption [2][4]. - The trial is a multinational, multicenter study that will explore early signals of efficacy, including reductions in alcohol consumption and cravings, which could facilitate further development of this therapy [4]. Group 2: Company Strategy and Goals - The activation of new clinical sites and participant enrollment is seen as a step closer to validating CMND-100's potential to transform the treatment landscape for AUD, reflecting the scientific community's interest in the company's approach [3][5]. - Clearmind's primary objective is to research and develop psychedelic-based compounds and commercialize them as regulated medicines, foods, or supplements, addressing widespread and underserved health problems [5]. Group 3: Intellectual Property - The company currently holds an intellectual portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents for its compounds as warranted [6].

Core Viewpoint - Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval for its Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][3][4] Group 1: Clinical Trial Details - The trial will take place at Tel Aviv Sourasky Medical Center (TASMC) and includes participation from other prestigious institutions such as Yale School of Medicine and Johns Hopkins University [2] - The trial aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD [4] Group 2: Company Background and Objectives - Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Group 3: Market Context and Impact - AUD is a significant global health issue, accounting for 4.7% of all deaths worldwide, highlighting the urgent need for effective treatments [4] - The company aims to provide a transformative treatment for individuals affected by AUD, which impacts millions of lives globally [4]